Anteris Technologies Global Corp. (AVR)
Anteris Technologies Global Corp. is a structural heart company focused on developing and commercializing innovative medical devices for aortic stenosis. Their lead product, DurAVR, is a transcatheter heart valve system designed to mimic a healthy human aortic valve.
Company Overview
Anteris Technologies pioneers next-generation heart valve technology with DurAVR, a potentially disruptive transcatheter aortic valve poised to capture significant market share in the rapidly growing aortic stenosis treatment space, offering superior hemodynamic performance and durability compared to existing solutions.
Investment Thesis
Anteris Technologies presents a compelling investment opportunity due to its innovative DurAVR transcatheter heart valve system, which addresses a significant unmet need in the aortic stenosis treatment market. The unique design of DurAVR, mimicking a healthy human aortic valve, has the potential to deliver superior hemodynamic performance and long-term durability compared to existing solutions. Positive clinical trial data could drive rapid adoption and market share gains. With a market cap of $0.18 billion, AVR offers substantial upside potential as it progresses through clinical trials and approaches commercialization. Key value drivers include successful completion of clinical trials, regulatory approvals, and strategic partnerships. The company's proprietary ADAPT tissue technology further enhances its competitive advantage and expands its potential applications.
Key Highlights
- Market capitalization of $0.18 billion reflects the company's growth potential in the structural heart market.
- Gross margin of 67.9% indicates strong pricing power and efficient operations.
- Beta of 0.51 suggests lower volatility compared to the overall market.
- Focus on DurAVR, a novel transcatheter heart valve system, positions the company to capitalize on the growing aortic stenosis treatment market.
- Proprietary ADAPT tissue technology provides a competitive advantage and expands potential applications.
Competitors
Strengths
- Innovative DurAVR valve design.
- Proprietary ADAPT tissue technology.
- Experienced management team.
- Strong intellectual property protection.
Weaknesses
- Reliance on a single lead product candidate (DurAVR).
- Limited commercialization experience.
- Negative profit margin (-3941.7%).
- Relatively small market capitalization.
Catalysts
- Upcoming: Completion of DurAVR clinical trials and publication of results.
- Upcoming: Regulatory approvals for DurAVR in key markets (e.g., United States, Europe).
- Ongoing: Strategic partnerships with leading hospitals and research institutions.
- Ongoing: Expansion of DurAVR clinical trials to include a broader patient population.
Risks
- Potential: Clinical trial failures or delays.
- Potential: Regulatory setbacks or denial of approvals.
- Potential: Competition from established medical device companies with greater resources.
- Potential: Product liability claims.
- Ongoing: Dependence on key personnel.
Growth Opportunities
- Expansion of DurAVR Clinical Trials: Anteris Technologies can expand its clinical trials to include a broader patient population and demonstrate the long-term efficacy and safety of DurAVR. Positive trial results will be crucial for securing regulatory approvals and driving adoption by physicians. The global TAVR market is expected to continue growing, providing a substantial opportunity for DurAVR to capture market share.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with leading hospitals and research institutions can accelerate the development and commercialization of DurAVR. Collaborations can also provide access to valuable resources and expertise, enhancing the company's competitive position. These partnerships could be initiated in the next 1-2 years.
- Geographic Expansion: Expanding into new geographic markets, such as Europe and Asia, can significantly increase the potential market for DurAVR. Regulatory approvals in these regions will be essential for market entry. The company can leverage its existing clinical data and partnerships to facilitate expansion efforts over the next 3-5 years.
- Development of Next-Generation Valve Technologies: Investing in the development of next-generation valve technologies can ensure Anteris Technologies remains at the forefront of the structural heart market. This includes exploring new materials, designs, and delivery systems to further improve patient outcomes. This is an ongoing process with continuous innovation.
- Application of ADAPT Tissue Technology in Other Areas: The company's proprietary ADAPT tissue technology has potential applications beyond aortic valve replacement. Exploring new applications in other areas of cardiovascular surgery and tissue engineering can diversify the company's revenue streams and create new growth opportunities. This could be explored over the next 2-3 years.
Opportunities
- Growing market for TAVR procedures.
- Potential for strategic partnerships.
- Expansion into new geographic markets.
- Application of ADAPT tissue technology in other areas.
Threats
- Competition from established medical device companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Product liability risks.
Competitive Advantages
- Proprietary DurAVR valve design mimicking a healthy human aortic valve.
- Patented ADAPT anti-calcification tissue technology.
- Physician-developed ComASUR delivery system.
- Strong intellectual property portfolio.
About
Anteris Technologies Global Corp., founded in 1999 and based in Toowong, Australia, is a structural heart company dedicated to enhancing the lives of patients suffering from aortic stenosis. The company focuses on discovering, developing, and commercializing advanced medical devices that address the limitations of current treatment options. Its flagship product candidate, the DurAVR transcatheter heart valve system, represents a significant advancement in aortic valve replacement technology. DurAVR is uniquely designed to mimic the natural shape and function of a healthy human aortic valve, potentially leading to improved hemodynamic performance and long-term durability compared to traditional valves. In addition to DurAVR, Anteris Technologies has developed ADAPT anti-calcification tissue, a proprietary technology that transforms xenograft tissue into durable bioscaffolds, making them suitable for surgical repair in various settings, including aortic valve replacement. The company also created the ComASUR delivery system, a physician-developed balloon expandable delivery system with a reinforced steerable catheter, enabling precise and controlled valve deployment while minimizing the risk of aortic damage. Anteris Technologies aims to establish itself as a leader in the structural heart market by providing innovative solutions that improve patient outcomes and quality of life.
What They Do
- Develops the DurAVR transcatheter heart valve system for aortic stenosis treatment.
- Creates ADAPT anti-calcification tissue for durable bioscaffolds.
- Designs the ComASUR delivery system for precise valve deployment.
- Focuses on enhancing the quality of life for patients with heart valve disease.
- Researches and innovates in the field of structural heart technology.
- Conducts clinical trials to evaluate the safety and efficacy of its products.
- Seeks regulatory approvals for its medical devices.
Business Model
- Develops and patents innovative medical device technologies.
- Conducts clinical trials to validate product performance.
- Seeks regulatory approvals for commercialization.
- Generates revenue through the sale of its medical devices.
Industry Context
The medical device industry, specifically the structural heart market, is experiencing significant growth driven by an aging population and increasing prevalence of aortic stenosis. The global market for transcatheter aortic valve replacement (TAVR) is projected to reach billions of dollars in the coming years. Anteris Technologies is positioned to capitalize on this growth with its DurAVR valve, which offers a differentiated approach compared to existing TAVR devices. Competitors include companies like ANIK (Anika Therapeutics, Inc.), ARAY (Accuray Incorporated), ATLN (AtriCure, Inc.), CYBN (Cybin Inc.), and LNSR (Lantheus Holdings, Inc.), but DurAVR's unique design could give it a competitive edge.
Key Customers
- Hospitals and cardiac centers.
- Cardiologists and cardiac surgeons.
- Patients with aortic stenosis.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $429,000 | -$22M | $-0.94 |
| Q2 2025 | $618,000 | -$21M | $-0.88 |
| Q1 2025 | $556,000 | -$22M | $-0.93 |
| Q4 2024 | $536,112 | -$19M | $-0.82 |
Source: Company filings
Chart & Info
Price Chart
Anteris Technologies Global Corp. (AVR) stock price: $4.78 (-0.14, -2.85%)
Why Bull
- •Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in the potential upside.
- •Community sentiment has shifted positively, with discussions highlighting the innovative nature of Anteris's technology and its applications in healthcare.
- •Analysts have noted increasing interest from institutional investors, signaling a growing belief in the company's long-term viability and market position.
- •Recent partnerships and collaborations have been perceived favorably, enhancing the company's credibility and potential for growth in the industry.
Why Bear
- •Concerns about market competition have surfaced, with some community members highlighting potential challenges Anteris may face from more established players.
- •Recent news regarding regulatory hurdles has created uncertainty, leading to skepticism about the company's ability to navigate these challenges effectively.
- •Some investors express caution due to the company's historical volatility, suggesting that past performance may impact future investor confidence.
- •Social sentiment reflects a divide, with bearish voices raising questions about the sustainability of the current growth trajectory and market demand for its products.
Latest News
-
Anteris Technologies price target lowered to $15 from $20 at Lake Street
Yahoo! Finance: AVR News · Jan 24, 2026
-
Anteris Technologies price target lowered to $15 from $20 at Lake Street
TipRanks · Jan 24, 2026
-
Retail investors who hold 25% of Anteris Technologies Global Corp. (ASX:AVR) gained 41%, institutions profited as well
Yahoo! Finance: AVR News · Jan 23, 2026
-
Retail investors who hold 25% of Anteris Technologies Global Corp. (ASX:AVR) gained 41%, institutions profited as well
Simply Wall St. · Jan 23, 2026
Technical Analysis
Rationale
AI-generated technical analysis for AVR including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Anteris Technologies Global Corp. (AVR) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for AVR.
Make a Prediction
Set your price target for Anteris Technologies Global Corp. (AVR), choose a timeframe, and track your prediction accuracy.
Current price: $4.78
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AVR.
Price Targets
Wall Street price target analysis for AVR.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 2/100
Revenue declined -1.2% YoY, signaling shrinking demand or market headwinds.
-
Gross Margin 10/100
Gross margin of 67.9% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 6/100
Adequate cash of $70M covers near-term needs but may require additional funding for aggressive expansion.
-
R&D Intensity 10/100
Investing 1903.5% of revenue in R&D signals heavy commitment to innovation and future product pipeline.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 7/100
Active trading at 3.50% daily turnover suggests elevated interest, which can increase volatility.
-
Price Momentum 6/100
Mixed technical signals (above sma50, above sma200); price trend is inconclusive and may consolidate.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates AVR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Anteris Technologies price target lowered to $15 from $20 at Lake Street
Anteris Technologies price target lowered to $15 from $20 at Lake Street
Retail investors who hold 25% of Anteris Technologies Global Corp. (ASX:AVR) gained 41%, institutions profited as well
Retail investors who hold 25% of Anteris Technologies Global Corp. (ASX:AVR) gained 41%, institutions profited as well
Frequently Asked Questions
What does Anteris Technologies Global Corp. do?
Anteris Technologies is a structural heart company focused on developing and commercializing innovative medical devices for the treatment of aortic stenosis. Its lead product candidate, DurAVR, is a transcatheter heart valve system designed to mimic the natural shape and function of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue and the ComASUR delivery system. Anteris aims to provide superior solutions for aortic valve replacement, improving patient outcomes and quality of life.
Is AVR stock a good buy?
AVR stock represents a high-risk, high-reward investment opportunity. The company's success hinges on the successful development and commercialization of DurAVR. Positive clinical trial data and regulatory approvals could drive significant stock appreciation. However, potential investors should be aware of the risks associated with clinical trials, regulatory hurdles, and competition. The negative P/E ratio of -1.54 and profit margin of -3941.7% reflect the company's current development stage and lack of profitability. A thorough assessment of the company's financials, pipeline, and market potential is essential before making an investment decision.
What are the main risks for AVR?
The main risks for AVR include clinical trial failures or delays, which could significantly impact the company's timeline and valuation. Regulatory setbacks or denial of approvals could also hinder commercialization efforts. Competition from established medical device companies with greater resources poses a significant threat. Product liability claims related to DurAVR could result in substantial financial losses. Additionally, the company's dependence on key personnel creates a risk if they were to leave the company.
Is AVR a good stock to buy?
Whether AVR is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the AVR MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is AVR data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for AVR?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to Anteris Technologies Global Corp..
Who are AVR's main competitors?
Anteris Technologies Global Corp.'s competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how AVR compares.
What do analysts say about AVR?
Analyst ratings and price targets for AVR are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is AVR's market cap?
Market capitalization reflects the total market value of AVR's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has AVR stock performed recently?
Check the Chart & Info tab for AVR's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in AVR?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for AVR-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling AVR?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for AVR.
Is AVR a good stock for beginners?
Anteris Technologies Global Corp. (AVR) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is AVR for first-time investors?
Every stock carries risk, including Anteris Technologies Global Corp. (AVR). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like AVR.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change. Investment in Anteris Technologies Global Corp. involves significant risks, and investors should conduct their own due diligence before making any investment decisions.